OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

February 4th 2020

Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Davids on Exciting Data With Acalabrutinib in CLL

February 4th 2020

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Goy on the Utility of Novel Agents in MCL

February 4th 2020

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).

Dr. Kahn on Rising Incidence in Gastric and CRC in Young Adult Patients

February 4th 2020

Amir Khan, MD, discusses the rising incidence of gastric and colorectal cancers in young adult patients.

Dr. Ueno on the Residual Cancer Burden and Immunotherapy in Inflammatory Breast Cancer

February 1st 2020

Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma

February 1st 2020

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Dr. Gadgeel on the Utility of Liquid Biopsies in Lung Cancer

January 31st 2020

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the utility of liquid biopsies in lung cancer.

Dr. Gutierrez on the Safety Profile of Pembrolizumab-Based Combos in NSCLC

January 31st 2020

Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).

Dr. Ciombor on the Goals of the COLOMATE Trial in mCRC

January 31st 2020

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

Dr. Marshall on Physician Burnout in Oncology

January 31st 2020

John L. Marshall, MD, discusses physician burnout in oncology.

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

January 31st 2020

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.

Dr. Liebman on Toxicities of BRAF Inhibitors in Melanoma

January 31st 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

Dr. Kreitman on the Use of Moxetumomab Pasudotox in Hairy Cell Leukemia

January 31st 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses the use of moxetumomab pasudotox-tdfk (Lumoxiti) in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL).

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

January 31st 2020

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL

January 31st 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).

Dr. Ghobrial on Triplet Regimen in Smoldering Myeloma

January 31st 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.

Dr. Braun on Evolution of Immunotherapy in Advanced Renal Cell Carcinoma

January 30th 2020

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung Cancer

January 30th 2020

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

January 30th 2020

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.